UnitedHealth Group (UNH) has completed one of the most dramatic rallies on Wall Street in recent weeks. From a low of roughly $256 in March 2026, the stock surged about 47% to a 52-week high of $404.15 — erasing a significant chunk of the damage from a two-year slide that had wiped out more than 40% of its value.

But that headline number is misleading. Behind the rally lies a tangled story: a federal criminal probe, a surprise CEO departure, a full Berkshire Hathaway exit, and the early stages of an earnings recovery that remains far from complete.

Why It Matters

UnitedHealth is the largest health insurer in the United States, generating roughly $450 billion in trailing 12-month revenue, employing 390,000 people, and operating across health insurance (UnitedHealthcare) and health services (Optum). Given its size, its reach over 50 million members, and its influence across the entire U.S. healthcare system, even minor regulatory news moves not just UNH but the entire managed-care sector.

The current market capitalization of roughly $355 billion represents a valuation that ranges from "deep value" to "value trap" depending on whom you ask.

The Bull Case

A blowout quarter. On April 21, 2026, UNH reported Q1 results that smashed estimates. Adjusted EPS came in at $7.23 versus consensus of $6.60 — a 9.5% beat. Revenue reached $111.7 billion. The medical benefit ratio (MBR) improved to 83.9%, better than feared. The company raised its full-year 2026 EPS guidance to above $18.25 (from above $17.75). All 25 analyst revisions in the last 30 days have been upward, with consensus now at $18.36.

Wall Street is turning bullish in force. Of 26 analysts covering the stock, the vast majority rate it a Buy (mean rating 1.71 out of 5). Goldman Sachs added UNH to its U.S. Conviction List with a $435 price target. Bank of America raised its target to $420. JPMorgan followed with $420. The median analyst target is $400 — meaning the stock trades roughly at fair value by that metric.

Insider buying signals conviction. Stephen Hemsley, who served as CEO from 2006 to 2017, returned from retirement to take the helm after Andrew Witty's unexpected departure in May 2025. That same month, he purchased 86,700 shares at an average of $288.57 — a $25 million personal investment. President John Rex bought roughly $5 million worth. Multiple directors also acquired shares. Since Hemsley's buy, the stock is up about 35%. Insider accumulation that heavy is a rare signal of management's confidence in intrinsic value.

A diversified moat. UNH's dual-engine structure — UnitedHealthcare (insurance scale) and Optum (higher-margin health services, pharmacy, data analytics) — provides both stability and growth. Optum has been the go-to driver for margin expansion even amid the reimbursement headwinds facing the insurance side. The franchise is deeply entrenched with employer-sponsored plans, government contracts, and provider networks.

The Bear Case

The DOJ investigation — unresolved and escalating. In July 2025, UnitedHealth confirmed that the Department of Justice had opened both criminal and civil investigations into its Medicare Advantage billing practices. The core allegation: the company inflated patient risk scores to overcharge the federal government. There is no settlement timeline, no date for resolution. Potential outcomes range from fines and clawbacks to forced practice changes — any of which could cost tens of billions. This is existential enough that it drove the stock to a 52-week low of $234.60.

Berkshire Hathaway fully exited. One of the loudest bearish signals came on May 18, 2026, when Berkshire Hathaway's 13F filing revealed it had sold its entire UNH position — roughly 5 million shares worth approximately $1.6 billion. Buffett's firm originally bought near 15-year lows around $271 and exited in full during the first quarter of 2026 — just as the rally took off. For value investors who track Berkshire as a bellwether, this is a chilling data point.

Earnings remain well below peak. In FY2024, UNH earned $25.70 per share. FY2025, the crisis year, saw EPS collapse 36% to $16.35. The FY2026 consensus of $18.36 is still 28% below the FY2024 peak. Even the FY2027 estimate of $20.76, which implies 13% growth, would not bring earnings back to pre-crisis levels. Revenue growth has slowed to roughly 2%, down from double digits before the crisis. The debt-to-equity ratio stands at 74%, and the current ratio of 0.80 indicates tight liquidity.

Valuation is no longer distressed. At a forward P/E of 18.8x (and trailing P/E of 29.4x), UNH has repriced significantly from the March lows. The easy recovery money has been captured. The stock is cheap relative to its five-year average, but it is not the deep bargain it was during the March sell-off.

What to Watch

Q2 earnings — late July. The next quarterly report is expected around July 28, 2026, with consensus EPS at $4.85. Another beat would reinforce the turnaround narrative. A miss — especially on medical cost trends — could shake confidence rapidly.

DOJ developments. Any news on the federal investigation — a settlement, a fine, or an indictment decision — would be the single most consequential event for the stock in the medium term. The situation echoes the regulatory overhangs that META and GOOGL faced in prior years, but with criminal exposure added.

Optum's margin trajectory. The Optum business line (health services, pharmacy, data) is the higher-growth, higher-margin engine. Steps like Optum Rx pricing transparency and prior-authorization reforms could accelerate or compress margins. Watch Optum's contribution to overall operating earnings.

Institutional flow patterns. Berkshire sold everything, but Capital World Investors boosted its stake by 23% and Charles Schwab increased holdings by 147% quarter-over-quarter. The Q2 13F filings in August will show whether the smart-money narrative is consolidation or dispersion.

The Bottom Line

UnitedHealth Group presents a textbook value-versus-catalyst dilemma. On one side: a stellar Q1 beat, improving profitability metrics, broad analyst support, and strong insider ownership signals. On the other: a criminal investigation whose magnitude is still unknown, a high-profile exit by the world's most famous value investor, and earnings that have not yet recovered to pre-crisis levels.

The rally from $256 to $404 has already priced in much of the "crisis discount." At 18.8x forward earnings, UNH is below its five-year average but no longer the deep value it was in March. The risk-reward has narrowed. For those who believe the DOJ probe ends in a manageable settlement and the earnings recovery continues, there may still be upside. For those who see a fading value play with federal exposure and a Berkshire-sized red flag, the easy gains are behind it.